Abstract: A humanized antibody, or a scFv, Fab, or F(ab?)2 thereof, includes: a heavy chain variable region, or a homologous variant thereof, wherein the heavy chain variable region includes: heavy chain framework regions, CDRH1 that has the sequence of SEQ ID NO:19, CDRH2 that has the sequence of SEQ ID NO:20, and CDRH3 that has the sequence of SEQ ID NO:21, wherein the heavy chain variable region and the homologous variant share at least 90% sequence identity in the heavy chain framework regions; and a light chain variable region, or a homologous variant thereof, that includes: light chain framework regions, CDRL1 that has the sequence of SEQ ID NO:22, CDRL2 that has the sequences of SEQ ID NO:23, and CDRL3 that has the sequences of SEQ ID NO:24, wherein the light chain variable region and the homologous variant share at least 90% sequence identity in the light chain framework regions.

Abstract: The invention provides Notch pathway inhibition with reduced toxicity.

Abstract: The present invention relates to methods for identifying and using modulators of FDF03 biological activity in vitro and in vivo that are useful in the treatment of cancer.

Abstract: A composition is provided that includes an anti-CD19 single chain variable fragment (scFv) conjugated to a tumor-associated antigen. The antigen can comprise a Her-2/neu protein, such as a Her-2/neu extracellular domain. Methods of eliciting an immune response are also provided along with methods of treating, or limiting the occurrence of, cancer in a subject.

Abstract: Methods for decreasing proliferation and preventing or treating a neuroendocrine cancer using an N-methyl D-aspartate-associated (NMDA) glutamate receptor antagonists or binding agent, such as an antibody, antibody fragment or peptide aptamer specific for a NMDA glutamate receptor, are disclosed.

Abstract: The present invention provides ICOSL specific antigen binding molecules which are isolated from immunized and synthetic Elasmobranchii derived libraries. In particular, the present invention relates to shark Variable New Antigen Receptor (VNAR) domains that specifically bind and neutralize the activity of human Induced Co-Stimulatory Ligand (ICOSL). The neutralizing VNAR domains are isolated from two independent sources; an immunized nurse shark library and a synthetic spiny dogfish framework fusion library. The molecules may be formulated as pharmaceutical compositions and used in medicine.

Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD123. The invention also relates to chimeric antigen receptor (CAR) specific to CD123, vectors encoding the same, and recombinant cells comprising the CD123 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CD123 binding domain.

Abstract: Herein is reported a method for reducing the aggregation of an immunoglobulin in solution comprising the steps of i) comparing the amino acid sequence of the fourth framework region of the heavy chain of an antibody with a reference or germline sequence and determining whether one or more threonine residues and/or serine residues have been replaced by a different amino acid residue, and ii) modifying the amino acid sequence of the immunoglobulin by reverting the exchanged threonine residues and/or serine residues back to threonine or serine of the reference or germline sequence and thereby reducing the aggregation of an immunoglobulin in solution.

Abstract: The present invention relates to an antibody which has a therapeutic effect on cancer, an autoimmune disease, or an inflammatory disease. That is, the present invention relates to an antibody which exhibits a cytotoxic activity against death domain-containing receptor-expressing cells through apoptosis. [Object] An object of the invention is to provide a pharmaceutical having a therapeutic effect on cancer. [Means for Resolution] A novel anti-DR5 antibody capable of inducing apoptosis in cells has more potent cytotoxic activity than currently available anti-DR5 antibodies.

Abstract: Human antibodies, preferably recombinant human antibodies, both humanized and chimeric, which specifically bind to human OX40 are disclosed. Preferred antibodies have high affinity for OX40 receptor and activate the receptor in vitro and in vivo. The antibody can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, are useful for modulating receptor activity, e.g., in a human subject suffering from a disorder in which OX40 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies are provided, and methods of synthesizing the recombinant human antibodies, are also provided.

Abstract: Provided herein are antibodies that immunospecifically bind to CD123. Also described are related polynucleotides capable of encoding the provided CD123-specific antibodies or antigen-binding fragments, cells expressing the provided antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments. In addition, methods of using the provided antibodies are described. For example, the provided antibodies may be used to diagnose, treat, or monitor CD123-expressing cancer progression, regression, or stability; to determine whether or not a patient should be treated for cancer; or to determine whether or not a subject is afflicted with CD123-expressing cancer and thus may be amenable to treatment with a CD123-specific anti-cancer therapeutic, such as the multispecific antibodies against CD123 and CD3 described herein.

Abstract: This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against KRTCAP3, FAM26F, MGC52498, FAM70A or TMEM154 antigens, which are differentially expressed in cancer, and diagnostic and therapeutic usages. This invention further relates to extracellular domains of KRTCAP3, FAM26F, MGC52498, FAM70A and TMEM154 proteins and variants, and therapeutic usages thereof.

Abstract: The present invention generally concerns formulations having a pH that inhibits aspartyl isomerization at an Asp-Asp motif in a therapeutic protein contained in such a formulation.

Abstract: An antibody recognizing the O-acetylated-GD2 ganglioside for the treatment of Cancer Stem Cells (CSC) cancer, a pharmaceutical composition including the antibody for treating a CSC cancer and a method for treating a CSC cancer in a patient in need thereof, the method including administering the antibody to the patient. A method for diagnosing a CSC, the use of the O-acetylated-GD2 ganglioside as a biomarker of CSC cancer, and a method for predicting the response of a subject affected with CSC cancer to a treatment with the antibody or the composition are also described.

Abstract: The present invention pertains to the field of cancer therapy using anti-cancer antibodies. The medical use of anti-EGFR antibodies having improved glycosylation characteristics, in particular a reduced fucosylation, is provided which show anti-cancer efficacy and an improved adverse side effect profile.

Abstract: Expression of GLUD1, GLUD2, or both is tested in gliomas, leukemias, or suspected gliomas and leukemias. Up-regulation of expression is found in IDH1/IDH2 mutant cancers. Inhibition of GLUD1, GLUD2, or both can be used therapeutically to inhibit cancer growth. Assays for GLUD1, GLUD2, or both GLUD1 expression can measure RNA or protein or enzyme activity, for example.

Abstract: The purpose of the present invention is to provide a novel monoclonal antibody having high affinity and that strictly recognizes, as a sugar chain epitope, only a “Sia?2,6Gal?1,4GlcNAc (6?-Sialyl-LacNAc): CDw75” sugar chain structure, being a molecular target for diagnosis of the malignancy of tumors. An anti-CDw75 monoclonal antibody is provided that recognizes “CDw75” sugar chain structures but does not recognize similar sugar chain structures indicated by “Gal?1,4GlcNAc”, “Sia?2,3Gal?1,4GlcNAc”, or “Sia?2,6Gal?1,4Glc”, by using a glycolipid antigen bonding a carrier lipid compound “HOCH2CH (NH—CO—(CH2)22—CH3)—(CH2)9—CH3 (C12L)” developed by the inventors to a “CDw75” sugar chain. The obtained anti-CDw75 monoclonal antibody is an excellent detection drug for B-cell lymphoma, gastric cancer, or colorectal cancer, an excellent diagnostic agent for tumor malignancy, etc.

Abstract: Antibodies that specifically bind to CD38, as well as constructs comprising such antibodies fused to attenuated interferon alpha-2B proteins are provided. Anti-CD38-attenuated interferon alpha-2b fusion constructs may be used to inhibit proliferation in cancerous cells that express both CD38 and the receptor for IFN-alpha2b, as well as to induce apoptosis in such cells. Inhibition of proliferation and induction of apoptosis in cancerous cells may serve as the basis for the treatment of the underlying cancer.

Abstract: Herein is reported an IgG class Fc-region comprising a first variant Fc-region polypeptide and a second variant Fc-region polypeptide, wherein the first variant Fc-region polypeptide is derived from a first parent IgG class Fc-region polypeptide and the second variant Fc-region polypeptide is derived from a second parent IgG class Fc-region polypeptide, whereby the first parent IgG class Fc-region polypeptide is identical to or different from the second parent IgG class Fc-region polypeptide, and the first variant Fc-region polypeptide differs from the second variant Fc-region polypeptide in one or more amino acid residues other than those amino acid residues in which the first parent IgG class Fc-region polypeptide differs from the second parent IgG class Fc-region polypeptide, and the IgG class Fc-region comprising the first variant Fc-region polypeptide and the second variant Fc-region polypeptide has an affinity to a human Fc-receptor that is different than that of an IgG class Fc-region comprising the fi

Abstract: Naphthalimide compounds are used in tissue bonding and protein cross-linking applications. When activated by an activating agent, such as light in the 400-500 nm absorption range, the naphthalimide compounds form chemically-reactive species that cross-link proteins, bond connective tissues together, and bond tissues and other biomaterials together. A naphthalimide-labeled biomolecule, such as a naphthalimide-labeled chitosan, is also capable of bonding tissues without subsequent direct illumination of the contacted tissue area. The naphthalimide compounds may be used in tissue or arterial repair, stabilization of an expanded arterial wall after angioplasty, tethering pharmaceutical agents to tissue surfaces to provide local drug delivery, and for chemically bonding skin care products, sunscreens, and cosmetics to the skin.

Abstract: The present invention relates to glycogen-based polymers and the use thereof for enhancing the solubility in water of lipophilic compounds, to complexes of the said glycogen-based polymers with lipophilic compounds and the use thereof for administering lipophilic compounds, and to pharmaceutical, nutraceutical, and cosmetic compositions comprising the said complexes.

Abstract: The present teachings show that it is possible to polymerize 1,1-disubstituted alkene compounds in a solution (for example using one or more solvents). Polymerization of 1,1-disubstituted alkene compounds in an solution provides opportunities to better control the polymerization compared with bulk polymerization. The solution polymerization techniques can be employed for preparing homopolymers, copolymers (e.g., random copolymers), and block copolymers.

Abstract: The Application of equations of state to experimental and literature data permits the formation of a model and phase diagram(s) that show under what conditions polyethylene is likely to precipitate out of a high pressure solution of polyethylene in supercritical ethylene. This then permits a better definition to run a high pressure reactor to reduce the likelihood of phase separation, loss of cooling and potentially decomposition of the reactor contents.

Abstract: The present teachings are directed at 1,1-disubstituted alkene monomers (e.g., methylene beta-diketone monomers), methods for producing the same, and compositions and products formed therefrom. In the method for producing the monomer, a beta-diketone is preferably reacted with a source of formaldehyde in a modified Knoevenagel reaction optionally in the presence of an acidic or basic catalyst, and optionally in the presence of an acidic or non-acidic solvent, to form reaction complex. The reaction complex may be an oligomeric complex. The reaction complex is subjected to vaporization in order to isolate the monomer. The monomer(s) may be employed in compositions and products, including monomer-based products (e.g., inks, adhesives, coatings, sealants or reactive molding) and polymer-based products (e.g., fibers, films, sheets, medical polymers, composite polymers and surfactants).

Abstract: An in situ method of preparing modified polyvinyl acetals is described with the aim of improving the alcohol tolerance while retaining barrier properties of the base polymer.

Abstract: The disclosed technology relates to pure polyitaconic acid homo- and co-polymers free of the less reactive tri-substituted vinyl monomers (e.g., citraconic acid or mesaconic acid) that may be used, for example, as builders in detergent applications, such as in the personal and home care market.

Abstract: The disclosure relates to compositions containing 1,1-disubstituted alkene compounds capable of preparing polymers having glass transition temperatures above room temperature. The present teaching also relates to polymers prepared 1,1-disubstituted alkene compounds which exhibit glass transition temperatures of 60° C. The disclosure also relate to methods for enhancing the glass transition temperatures of polymers prepared from 1,1-disubstituted alkene compounds.

Abstract: This invention relates to base oils for lubricating compositions. In particular, the present invention provides a process for the selective oligomerisation of C5 to C20 alpha-olefins to produce polyalphaolefin oligomers with a molecular weight distribution that is suitable for use in lubricant base oils.

Abstract: A polyethylene composition comprising at least 95 percent by weight of the units derived from ethylene; less than 5 percent by weight of units derived from one or more ?-olefin comonomers; wherein said polyethylene composition has a density in the range of 0.930 to 0.945 g/cm3, a molecular weight distribution characterized by the ratio of the z-average molecular weight to the weight average molecular weight (Mz/Mw) less than 5, a melt index, I2 (measured at 190° C., 2.16 kg), in the range of 0.08 to 0.5 g/10 minutes, and a high flow melt index, I21 (measured at 190° C., 21.

Abstract: The present application relates to a propylene ethylene random copolymer exhibiting two melting temperatures (Tm) which differ from each other.

Abstract: Disclosed herein are ethylene-based polymers having a melt index less than 50 g/10 min, a ratio of Mw/Mn from 4 to 20, a density from 0.90 to 0.945 g/cm3, and a substantially constant short chain branch distribution. These polymers can be produced using a dual catalyst system containing a boron bridged metallocene compound with a cyclopentadienyl group and an indenyl group, and a single atom bridged metallocene compound with a fluorenyl group.

Abstract: The invention relates to a multilayer structure comprising at least one layer of supramolecular material and one layer of rigid material, to a method for producing such a structure by casting a composition comprising a precursor of the supramolecular material, and to the uses of the structures produced, especially for applications where a dampening of impacts, vibrations and/or sound waves is desired, for example for producing locomotion vehicles such as automotive, rail, nautical, aeronautical or aerospace vehicles, or for the construction industry.

Abstract: Described herein is a curable composition comprising: a crosslinkable epoxy resin; a curing agent; and a compound, wherein the compound comprises a pyrazine moiety but not a primary amine

Abstract: A method for producing high-molecular poly-L lactic acid by directly polycondensating L-lactic acid using a melt-phase condensation and a subsequent solid-phase condensation using acidic and supported solid catalysts. A method of using an acidic and supported solid catalyst for producing high-molecular poly-L lactic acid by directly polycondensating L-lactic acid, preferably supported and calcined zirconium sulfate is also disclosed.

Abstract: There are provided a polyester based copolymer resin capable of having an excellent shrinkage rate and being heat-shrunk at a low temperature, and a molded product comprising the same. The polyester based copolymer resin includes a dicarboxylic acid-derived residue including a residue derived from an aromatic dicarboxylic acid; and a diol-derived residue including a predetermined residue derived from 4-(hydroxymethyl)cyclohexylmethyl 4?-(hydroxymethyl)cyclohexane carboxylate and a predetermined residue derived from 4,4-(oxybis(methylene)bis)cyclohexane methanol.

Abstract: A process for the preparation of polycarbonates may include ring-opening polymerization of five-membered cyclic carbonates in the presence of a catalyst; a compound of formula (I), stereoisomers, racemics, or mixtures thereof; and optionally cyclic esters, stereoisomers, racemics, or mixtures thereof. Formula (I) is: Each dotted bond “a” and “b” is a solid bond, a wedged bond, or a hashed wedged bond. R21 and R22, taken together with the carbon atoms 4 and 5 of the cyclic carbonate, may form a ring. The ring may be a C5-9cycloalkylene, C5-9cycloalkenylene, or C6-12arylene. The ring may optionally be substituted with substituents including halo, hydroxyl, C1-6alkyl, haloC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy, C6-12aryl, C1-6alkylthio, carboxyl, C1-6alkoxycarbonyl, C1-6alkylcarbonyloxy, amino; or mono- or di-C1-6alkylamino.

Abstract: The present invention relates to a double metal cyanide (DMC) complex catalyst with an improved catalytic activity useful for epoxide polymerization. It also relates to polyether polyols prepared by a polymerization reaction using said DMC catalyst.

Abstract: A continuous process for producing a nylon salt solution prepared using a liquid partially balanced acid solution enriched in dicarboxylic acid, and in particular adipic acid. The liquid feed is prepared by metering dicarboxylic acid powder, based on weight, from a loss-in-weight feeder to a feeding conduit that transfers the dicarboxylic acid powder into an in-line disperser; feeding a first feed stream of diamine to the in-line disperser to form a dispersion comprising between 32 wt. % and 46 wt. % dicarboxylic acid, between 11 wt. % and 15 wt. % diamine, and between 39 wt. % and 57 wt. % water, and heating the dispersion at temperature between 50 C and 60 C to form a partially balanced acid solution. A nylon salt solution is prepared from the liquid partially balanced acid solution and continuously withdrawn into a storage tank. The nylon salt solution has a uniform pH and is suitable for producing nylon polymers.

Abstract: The present disclosure relates to systems and methods for recovering water from a condensation reaction of at least one carboxylic acid and at least one diamine to make polyamide. The method can include obtaining, from an evaporator, an aqueous mixture comprising a partially polymerized polyamide and at least one of a carboxylic acid and diamine; passing the aqueous mixture through a tubular reactor comprising subjecting the aqueous mixture to a temperature and pressure sufficient to further polymerize the partially polymerized polyamide by condensation of the carboxylic acid and diamine, thereby producing water having a substantially gaseous phase; passing the water having a substantially gaseous phase into a rectification column thereby removing one or more of a diamine, a carboxylic acid and polyamide to provide purified water having a substantially gaseous phase; and condensing the purified water having a substantially gaseous phase into purified water having a substantially liquid phase.

Abstract: Disclosed are process controls for controlling the continuous preparation of nylon salt solution. The process controls include feed forward controls. A model is generated to achieve a target pH and/or salt concentration. Feed rates are set for each of a dicarboxylic acid monomer, a diamine monomer, and/or water to a single continuous stirred tank reactor. The dicarboxylic acid is metered, based on weight, from a loss-in-weight feeder to the reactor. The nylon salt solution is formed continuously and has low variability from a target pH and/or a target salt solution concentration. The nylon salt solution is transferred directly to a storage tank, without further monomer addition, pH adjustment, or salt solution adjustment after exiting the continuous stirred tank reactor.

Abstract: Monomer embodiments that can be used to make polymers, such as homopolymers, heteropolymers, and that can be used in particular embodiments to make sequence-defined polymers are described. Also described are methods of making polymers using such monomer embodiments. Methods of using the polymers also are described.

Abstract: PROBLEM: To provide a method of producing a polyarylene sulfide (PAS) such as polyphenylene sulfide (PPS) in which a dihalo aromatic compound and a sulfur source containing an alkali metal are polymerized in an organic amide solvent, whereby a PAS is produced at higher yield and the amount of NaCl produced as a by-product is reduced to not greater than half that of conventional methods, and, due to a dehydration step being omissible, PAS with excellent practical utility is produced with high productivity in a short time. SOLUTION: A method of producing a PAS in which a dihalo aromatic sulfide compound represented by the formula: X—(—Ar—S—)n—Ar—X (in the formula, Ar represents an optionally substituted aromatic group, X represents a halogen atom, and n is from 1 to 10) and a sulfur source containing an alkali metal are polymerized in an organic amide solvent; and a PAS of which an average particle size is from 10 to 5000 ?m, a melt viscosity measured at a temperature of 310° C.

Abstract: The mechanical properties of urea formaldehyde resins may be improved by incorporating therein polyvinyl alcohol. The polyvinyl alcohol may be incorporated during pre-mixing, mid mixing, and/or post mixing of the resin components. Resins prepared using polyvinyl alcohol are particularly desirable in articles requiring improved mechanical strength and water resistance, as compared to similar resins prepared without the polyvinyl alcohol such as shingles.

Abstract: In one aspect, the present invention pertains to novel block materials comprising an aliphatic polycarbonate (APC) chain bound to a hydrocarbon. The invention also provides methods of making the block materials and using them as compatibilizers for polymer blends. In another aspect, the present invention encompasses methods of making blends of APCs with polyolefins. In certain embodiments, the methods comprise the step of blending one or more APCs with one or more polyolefins in the presence of a compatibilizer as described herein. In another aspect, the present invention encompasses novel blends of APCs with polyolefins. In certain embodiments, the blends comprise one or more APCs; at least one polyolefin and a compatibilizer as described herein.

Abstract: A thiol-ene polymeric material is disclosed. The material is produced by the photopolymerization of reactants having thiol and olefin moieties. The material can incorporate encapsulated components, including cells. Additionally, the material can be derivatized by reacting the polymeric material with components such as proteins.

Abstract: Embodiments of the present disclosure include organic polymeric particles, paper coating compositions, coated paper, and methods of forming coated paper with the paper coating compositions. The embodiments of the organic polymeric particle include an organic hydrophilic polymer with a unit for hydrogen bonding, and a hollow porous structure that comprises an organic polymer that at least partially surrounds the organic hydrophilic polymer, where the hollow porous structure has a pore surface area greater than 1 percent of a total theoretical exterior surface area of the hollow porous structure and the organic hydrophilic polymer and the hollow porous structure give the organic polymeric particle a void volume fraction of 40 percent to 85 percent.

Abstract: An emulsion-derived particle comprises a lattice of polymeric strands cross-linked by means of a cross-linking agent, and interstitial openings adjacent and around the strands. Functional groups are provided on the lattice and proteins and/or modified proteins can react with these, thereby to be bonded to the lattice and hence immobilised.

Abstract: A solution based polymer nanofiller composite processing method to improve mechanical, electrical, thermal and/or chemical properties. The solution based synthesis method may include the steps of surface functionalizing carbon nanomaterials and dissolving a polymer in a solvent. The functionalized carbon nanomaterials and dissolved polymer may be mixed until the mixture is homogenous. The mixture may be cured to form the polymer carbon nano-composite material, which provides significant improvements in modulus, hardness, strength, fracture toughness, wear, fatigue, creep, and damping performance.

Abstract: The invention relates to a method for producing a dispersion of nanoscale dicarboxylic acid salts, to the use of these dispersions for producing a compound, and to the use for producing films. The invention further relates to the use of the compounds for producing films.

Abstract: The present application relates to a natural fiber plastic composite product comprising thermoplastic polymer and dried deinking sludge containing cellulose fibers and minerals in foamed form. The present application also relates to a method for preparing the natural fiber plastic composite product.